铁校正MRI评估MASH活动度预测2型糖尿病胰岛素抵抗与心血管代谢风险
在109例基层2型糖尿病患者中,按铁校正T1 mapping(cT1)和肝脂肪含量分为无脂肪变、单纯脂肪变、轻中度MASH(cT1 ≥800至≤875 ms)和重度MASH(cT1 >875 ms)四组。研究发现cT1越高,代谢综合征特征越重、胰岛素抵抗(HOMA-IR)和脂肪组织功能障碍(Adipo-IR升高、脂联素降低)越明显,且与肝坏死性炎症和纤维化非侵袭性指标恶化相关。
要点
- cT1评估的MASH活动度升高与2型糖尿病患者胰岛素抵抗和脂肪组织功能障碍相关。
- cT1升高同时与肝坏死性炎症(FAST、NIS2+®、CK-18)及脂肪变和纤维化严重程度相关。
- 在基层2型糖尿病人群中使用cT1可能有助于早期识别需要积极干预的高危个体。
核心结论
- 在2型糖尿病患者中,cT1评估的MASH活动度越差,与驱动肝病进展的心血管代谢危险因素(胰岛素抵抗、脂毒性、代谢综合征)的关联越显著。
研究设计与样本
- 从基层医疗机构招募109例2型糖尿病参与者,根据cT1和肝脂肪含量(LiverMultiScan)分为四组:无脂肪变、单纯脂肪变无MASH、轻中度MASH(cT1 ≥800至≤875 ms)、重度MASH(cT1 >875 ms)。
主要发现
- 更高的MASH活动度(cT1)与更严重的代谢综合征特征、胰岛素抵抗(HOMA-IR)增加及脂肪组织功能障碍(Adipo-IR升高、脂联素降低)相关(所有P < .01)。
- cT1升高与肝坏死性炎症(FAST、NIS2+®、CK-18)更差及脂肪变和纤维化更严重相关(所有P < .001)。
关键数值与推荐
- MASH分组阈值:轻中度MASH为cT1 ≥800至≤875 ms,重度MASH为cT1 >875 ms。
- 代谢相关指标关联的P值均< .01;肝坏死性炎症和纤维化指标关联的P值均< .001。
临床怎么用
- 在基层2型糖尿病人群中,可考虑使用cT1进行MASH风险分层,早期识别心血管代谢风险较高、可能受益于更积极干预的个体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Multiparametric magnetic resonance iron-corrected T1 mapping (cT1) may help identification and risk-stratification of steatohepatitis (MASH). OBJECTIVE: In type 2 diabetes, metabolic dysfunction-associated steatotic liver disease frequently advances to steatohepatitis with significant fibrosis and increased risk of developing cirrhosis. cT1 allows MASH risk-stratification by measuring liver disease activity (fibro-inflammation) but its association with cardiometabolic risk factors that drive liver disease progression in T2D (insulin resistance, lipotoxicity, and metabolic syndrome) remains unclear. METHODS: We recruited 109 participants with T2D from primary care settings who were classified into four groups according to cT1 and liver fat content (LiverMultiScan): (1) without steatosis; (2) steatosis only without MASH; (3) mild-moderate MASH (cT1 ≥ 800 to ≤875 ms); and (4) severe MASH (cT1 > 875 ms). We also measured insulin resistance (HOMA-IR), adipose tissue dysfunction (Adipo-IR, plasma adiponectin), and several noninvasive tests of MASH necroinflammation or fibrosis severity (NIS2+®, CK-18, FAST, and MRE). RESULTS: Higher MASH disease activity (cT1) was associated with more severe features of the metabolic syndrome as well as increased insulin resistance (HOMA-IR) and adipose tissue dysfunction (higher Adipo-IR and decreased adiponectin levels; all P < .01). Elevated cT1 correlated with worse hepatic necroinflammation (FAST, NIS2+®, and CK-18) and more severe steatosis and fibrosis (all P < .001). CONCLUSION: In people with T2D, worse MASH disease activity (measured by cT1) is associated with unfavorable cardiometabolic risk factors that are known to drive liver disease progression. Use of cT1 in this population may help early identification of at-risk individuals who would benefit from earlier aggressive intervention in primary care.
引用
- Ortiz Rocha A, Kalavalapalli S, Godinez Leiva E, et al. Severity of MASH activity by iron-corrected MRI predicts insulin resistance and cardiometabolic risk in type 2 diabetes. J Clin Endocrinol Metab. 2026. PMID: 41669855. doi:10.1210/clinem/dgag042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。